Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a higher number of deaths among patients who were taking the drug than among those taking a placebo. The study was testing the drug on previously untreated, elderly patients with B-cell chronic lymphocytic leukemia. All other Revlimid trials for chronic lymphocytic leukemia are proceeding. (PR)